Should You Continue to Hold RMD Stock in Your Portfolio?

ResMed reported continuing top-line strength driven by its mask portfolio and software acquisitions: Masks and related revenues rose 12% year‑over‑year in Q1 FY2026 across the U.S., Canada and Latin America, Residential Care Software revenue grew 6% (5% in constant currency), and combined regional sales were up ~10%. Management is expanding internationally and launching new AirTouch F30i variants while integrating acquisitions (MEDIFOX DAN, MatrixCare, Brightree, VirtuOx) to drive recurring revenue; Zacks consensus for FY2026 EPS is $10.81 and revenue $5.57B (+8.3% YoY). Key risks include macroeconomic pressures, tariffs/supply‑chain costs, FX volatility and intense competition (Philips, DeVilbiss), which temper but do not negate current operational momentum.

Analysis

Market structure: ResMed (RMD) is a beneficiary of durable resupply economics — masks and consumables growing ~12% YoY signal sticky recurring revenue; winners include RMD, its acquired software platforms (MatrixCare/Brightree) and suppliers of medical-grade polymers/electronics. Losers are smaller regional mask OEMs and price-sensitive distributors who can't match RMD’s IP and integrated software+hardware bundle. Competitive dynamics favor incumbents with scale in distribution and software; consolidation among payers/providers could compress device margins but expand SaaS pricing power for RMD if it converts customers to subscription models. FX and component cost volatility are the main supply-side constraints; bond markets may tighten for weaker medtech credits if margins compress, while RMD equity should show lower beta relative to cyclical healthcare names.

Risk assessment: Tail risks include an FDA recall or major reimbursement cut (CMS) that would knock >10% off RMD revenues in 12 months, and a supplier tariff shock raising COGS by >200–300 bps. Immediate risks (days–weeks) are earnings/guide misses and currency moves; short-term (1–6 months) is integration execution of VirtuOx and RCS consolidation; long-term (1–5 years) is vertical integration by large competitors or payers. Hidden dependencies: SaaS churn and conversion rates (need >15% ARR growth to justify software multiple expansion) and VirtuOx diagnostic margins. Catalysts to watch: next quarterly guide, CMS reimbursement notices (3–6 months), and Philips strategic moves.

Trade implications: Tactical: establish a modest long (1–2% NAV) in RMD to capture mask resupply and RCS SaaS optionality, funded by trimming small-cap OEM exposures. Pair trade: long RMD / short regional OEM ETF or Philips (if accessible) to isolate product share gains; target relative outperformance of 300–500 bps over 6–12 months. Options: buy 6-month 5% OTM calls sized 0.5% NAV to play product adoption upside and buy 3-month 7% OTM puts (0.5% NAV) as protection; alternatively sell 90-day covered calls post-purchase to finance puts if neutral-to-mildly bullish. Rotate: overweight MedTech leaders (RMD, MDT, BSX) and underweight commoditized respiratory equipment distributors.

Contrarian angles: Street underestimates RMD’s software margin optionality — if RCS ARR growth eclipses 15% and gross margins expand 200–300 bps, valuation re-rating is plausible within 12–24 months. Market may be underpricing resilience of resupply revenue (repeatable 10%+ growth) and overpricing recall risk; conversely expansion into lower-priced EM markets could compress blended ASPs before SaaS offset. Historical parallel: Philips’ recall-era share disruptions led to durable share gains for competitors; similar upside is possible for RMD if it sustains innovation and supply reliability. Watch for unintended consequence: aggressive discounting to win EM share could undermine global pricing — treat any guidance that implies >3% ASP erosion as a sell trigger.

Key Decisions for Investors

• Establish a 1.5% NAV long position in RMD within 2–6 weeks to capture ongoing mask resupply (12% YoY) and RCS SaaS upside; set a stop loss at -12% absolute or if company lowers FY26 revenue guide by >3% on release.
• Implement a pair trade: long RMD (1–1.5% NAV) and short a small-cap respiratory-equipment ETF or a liquid European Philips listing (PHG) sized 0.75–1.0% NAV to hedge macro/systematic risk; target relative return +300–500 bps in 6–12 months.
• Buy 6-month RMD calls ~5% OTM equal to 0.5% NAV and simultaneously buy 3-month 7% OTM puts equal to 0.5% NAV as asymmetric directional exposure with built-in protection; if IV falls, consider selling 90-day covered calls to finance puts.
• Reduce exposure by 2–4% to distributors/commodity respiratory OEMs now; reallocate proceeds to RMD/MDT/BSX — favor those with software or service annuity streams — and revisit after CMS reimbursement announcements (expected window 3–6 months).
• Monitor three metrics weekly: mask resupply revenue growth (target >8–10% YoY for bullish), RCS ARR growth (target >15% annualized), and any CMS/regulatory notices; act (scale up or exit) if two of three miss targets by >200 bps over a rolling quarter.